Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

3.235 -0.035 (-1.07%)
Streaming Delayed Price Updated: 1:55 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,248,750
Open 3.220
Bid (Size) 3.230 (23)
Ask (Size) 3.240 (16)
Prev. Close 3.270
Today's Range 3.180 - 3.320
52wk Range 3.220 - 11.69
Shares Outstanding 81,632,619
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
Where Editas Medicine Stands With Analysts
Via Benzinga

Performance

YTD
-67.59%
-67.59%
1 Month
-7.31%
-7.31%
3 Month
-28.74%
-28.74%
6 Month
-52.91%
-52.91%
1 Year
-54.69%
-54.69%

More News

Read More
Looking for Stock Bargains With Room to Run? Try This.
Via The Motley Fool
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Unveiling 5 Analyst Insights On Editas Medicine
Via Benzinga
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Via Benzinga
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Via InvestorPlace
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Via InvestorPlace
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Overlooked and Undervalued: 3 Stocks With Jaw-Dropping Upside Potential
Via InvestorPlace
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Via The Motley Fool
EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Editas Medicine Announces First Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.